Olutasidenib
2024-0515
Phase 2 small_molecule terminated
Quick answer
Olutasidenib for Chronic Myelomonocytic Leukemia is a Phase 2 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Chronic Myelomonocytic Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated